|

MTH1 Protein: A New Ally in the Fight Against Mesothelioma

ByHolly Zink
MTH1 Protein: A New Ally in the Fight Against Mesothelioma

Scientists are now investigating a protein known as MTH1. They are delving into its role in boosting the body’s immune response against mesothelioma. This groundbreaking research holds the promise of more effective treatments for patients.

Enhancing Mesothelioma Immunotherapy

Mesothelioma is a challenging type of cancer that affects the lining of organs like the lungs. It is caused by exposure to asbestos, a toxic mineral used in construction and manufacturing. Scientists have been studying a protein called MTH1. They are looking at its potential role in helping the body’s immune system respond to this cancer. This research could lead to more effective treatments for mesothelioma patients.

MTH1 is a protein that might have a significant impact on how the immune system responds to mesothelioma. But scientists are not entirely sure how it works yet. Figuring out how MTH1 works could make immunotherapy more effective.

Immunotherapy is a type of cancer treatment that tries to stimulate an immune response in the patient’s body to fight the cancer cells. Scientists think that MTH1 could play an important role in regulating the immune system. And it could make a type of immunotherapy, called anti-PD-L1, work even better.

MTH1 Inhibitors and Immunotherapy

One of the key focuses of a new study out of Greece was on special immune cells. They are called tumor-associated macrophages. These cells are essential in the body’s defense against cancer. The scientists believe that understanding MTH1 could unlock new ways to fight mesothelioma.

In this study, scientists used a medicine called karonudib to stop MTH1. They found that it boosted the strength of a specific type of macrophage called M1. This means the immune system was better equipped to attack the cancer. It also helped another group of immune cells, called CD8, become more active and effective.

In addition to helping the macrophages, interfering with MTH1 also activated other important immune cells like T cells. This created a powerful group of immune cells ready to fight against mesothelioma.

But the really exciting part was when they combined the MTH1 inhibitor with the anti-PD-L1 immunotherapy. Together, they were even more effective at slowing down mesothelioma tumor growth. And better at reducing the build-up of fluid around the lungs, which is a common problem in mesothelioma.

This research could mean a brighter future for people with mesothelioma. By understanding how MTH1 works and how it interacts with the immune system, scientists are getting closer to finding better treatments.

Source

Magkouta SF, Vaitsi PC, Iliopoulou MP, et al. MTH1 Inhibition Alleviates Immune Suppression and Enhances the Efficacy of Anti-PD-L1 Immunotherapy in Experimental Mesothelioma. Cancers (Basel). 2023;15(20):4962. Published 2023 Oct 12. doi:10.3390/cancers15204962. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605650/

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…

  • | |

    Value of Mesothelioma Surgery Challenged for Healthy Patients

    ByAlex Strauss

    New research conducted in Italy and presented at the 15th World Conference on Lung Cancer in Sydney, Australia suggests that mesothelioma surgery – no matter what kind – may not offer a survival advantage over medical management for the healthiest of patients. Mesothelioma is a rare but aggressive malignancy that is highly resistant to standard cancer treatments. The two types of mesothelioma surgery considered to be options for people with resectable cancer are pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP). While EPP is more radical than P/D because it involves removing a lung, both carry a heavy risk of complications and, according to the Italian researchers, may not be of value for certain patients. The study reviewed data from 1,365…